DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Zepbound (tirzepatide) for chronic weight management, OSA with obesity. Not covered under Medicare.
Medicare Part D covers GLP-1s for type 2 diabetes (Ozempic, Mounjaro) but historically excluded weight-loss indications. The 2026 CMS rule expanded Wegovy coverage for cardiovascular risk reduction in qualifying enrollees.
Medicare excludes weight-loss-only drugs. OSA pathway: some Medicare Advantage plans cover Zepbound for OSA with obesity (AHI ≥ 15 + BMI ≥ 30).
LillyDirect $349-499/mo.
OSA pathway is the route. Sleep study first.
Editorial summary, not legal or medical advice. Insurance formularies change quarterly. Verify with your specific plan member services before relying on any single source. Copay ranges reflect typical commercial plans; your plan may differ.